Investors & Media

Transformative science, targeted medicines

Blueprint Medicines, a Sanofi company, is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4 Statement of changes in beneficial ownership of securities View HTML
0001179110-16-018640.pdf
0001179110-16-018640.rtf
0001179110-16-018640.xls
3 Initial filing by director officer or owner of more than ten percent. View HTML
0001179110-16-018638.pdf
0001179110-16-018638.rtf
0001179110-16-018638.xls
CT ORDER CT ORDER
9999999997-16-016557.pdf
4 Statement of changes in beneficial ownership of securities View HTML
0001179110-16-018338.pdf
0001179110-16-018338.rtf
0001179110-16-018338.xls
3 Initial filing by director officer or owner of more than ten percent. View HTML
0001179110-16-017730.pdf
0001179110-16-017730.rtf
0001179110-16-017730.xls
8-K Report of unscheduled material events or corporate event View HTML
0001104659-16-088993.pdf
0001104659-16-088993.rtf
0001104659-16-088993.xls
8-K Report of unscheduled material events or corporate event View HTML
0001558370-16-002941.pdf
0001558370-16-002941.rtf
0001558370-16-002941.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001179110-15-016448.pdf
0001179110-15-016448.rtf
0001179110-15-016448.xls
SC 13G/A An amendment to the SC 13G filing View HTML
0000315066-15-003362.pdf
0000315066-15-003362.rtf
4 Statement of changes in beneficial ownership of securities View HTML
0001179110-15-015576.pdf
0001179110-15-015576.rtf
0001179110-15-015576.xls